Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,399 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
Shore T, Harpel J, Schuster MW, Roboz GJ, Leonard JP, Coleman M, Feldman EJ, Silver RT. Shore T, et al. Biol Blood Marrow Transplant. 2006 Aug;12(8):868-75. doi: 10.1016/j.bbmt.2006.05.006. Biol Blood Marrow Transplant. 2006. PMID: 16864057 Free article. Clinical Trial.
A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia.
Gergis U, Roboz G, Shore T, Ritchie E, Mayer S, Wissa U, McKenna M, Christos P, Pearse R, Mark T, Scandura J, van Besien K, Feldman E. Gergis U, et al. Among authors: feldman e. Biol Blood Marrow Transplant. 2013 Jul;19(7):1040-5. doi: 10.1016/j.bbmt.2013.04.013. Epub 2013 May 4. Biol Blood Marrow Transplant. 2013. PMID: 23648237 Free article. Clinical Trial.
Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment.
Gergis U, Kuriakose E, Shore T, Mayer S, Mark T, Pearse R, Schuster M, Feldman E, Roboz G, Ritchie E, Scandura J, Wang H, Zhou XK, Silver RT, van Besien K. Gergis U, et al. Among authors: feldman e. Clin Lymphoma Myeloma Leuk. 2016 May;16(5):297-303. doi: 10.1016/j.clml.2016.02.004. Epub 2016 Feb 18. Clin Lymphoma Myeloma Leuk. 2016. PMID: 27025789
Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies.
Martin P, Chadburn A, Christos P, Furman R, Ruan J, Joyce MA, Fusco E, Glynn P, Elstrom R, Niesvizky R, Feldman EJ, Shore TB, Schuster MW, Ely S, Knowles DM, Chen-Kiang S, Coleman M, Leonard JP. Martin P, et al. Among authors: feldman ej. Ann Oncol. 2008 Jul;19(7):1327-1330. doi: 10.1093/annonc/mdn045. Epub 2008 Mar 17. Ann Oncol. 2008. PMID: 18349031 Free article.
Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia.
Feldman EJ, Brandwein J, Stone R, Kalaycio M, Moore J, O'Connor J, Wedel N, Roboz GJ, Miller C, Chopra R, Jurcic JC, Brown R, Ehmann WC, Schulman P, Frankel SR, De Angelo D, Scheinberg D. Feldman EJ, et al. J Clin Oncol. 2005 Jun 20;23(18):4110-6. doi: 10.1200/JCO.2005.09.133. J Clin Oncol. 2005. PMID: 15961759 Clinical Trial.
1,399 results